Armour Thyroid Mechanism of Action: Full Pathway From Absorption to Nuclear Receptor Binding

What Armour Thyroid Contains and Why the Dual-Hormone Profile Matters

Armour Thyroid is a natural desiccated thyroid (NDT) product derived from porcine thyroid glands, standardized to deliver a fixed ratio of T4 and T3 in every tablet. Each grain (60 mg) provides approximately 38 mcg of levothyroxine (T4) and 9 mcg of liothyronine (T3), a weight-based ratio of roughly 4.2:1 [1].

That ratio differs from human physiology. The normal human thyroid gland secretes T4 and T3 at approximately a 14:1 molar ratio, meaning NDT delivers proportionally more T3 per unit of T4 than the body would produce endogenously [2]. This pharmacologic distinction drives much of Armour Thyroid's clinical behavior: peak serum T3 levels after a dose are higher and arrive faster than they would with levothyroxine monotherapy, where T3 generation depends entirely on peripheral conversion [3].

The porcine origin is not arbitrary. Pig thyroid tissue contains thyroglobulin-bound T4 and T3 in a biologically organized matrix, along with trace amounts of diiodothyronine (T2) and monoiodothyronine (T1) [1]. Whether these trace iodothyronines carry physiologic relevance in humans remains an open question, though preclinical data suggest T2 may influence mitochondrial respiration independently of classical nuclear receptor pathways [4].

Oral Absorption: How T4 and T3 Enter the Bloodstream

T4 and T3 follow distinct absorption kinetics after an oral dose of Armour Thyroid. Both hormones are absorbed primarily in the jejunum and upper ileum, but their bioavailability and time-to-peak differ substantially.

T4 oral bioavailability ranges from 40 to 80 percent in the fasting state, with peak serum levels occurring 2 to 4 hours post-dose [5]. Food, calcium supplements, iron, and proton pump inhibitors all reduce T4 absorption. The T3 component absorbs more rapidly and more completely, with bioavailability approaching 95 percent and peak serum concentrations arriving within 1 to 2 hours [6]. This creates a biphasic pharmacokinetic profile unique to NDT products: an early T3 surge followed by sustained T4 delivery.

Once absorbed, both hormones bind plasma carrier proteins. Approximately 99.97 percent of circulating T4 is protein-bound, primarily to thyroxine-binding globulin (TBG), with smaller fractions on transthyretin and albumin [5]. T3 binds these same proteins but with lower affinity, leaving a larger free fraction (approximately 0.3 percent free T3 versus 0.03 percent free T4). Only the free, unbound fractions are biologically active.

The practical consequence: after swallowing an Armour Thyroid tablet, serum free T3 rises measurably within 60 to 90 minutes, while free T4 accumulates more gradually over days to weeks of consistent dosing [3].

Peripheral Conversion: The Deiodinase System That Activates T4

T4 is a prohormone. It carries four iodine atoms and has minimal direct receptor affinity. The body's primary activation step is outer-ring deiodination, which removes one iodine atom from T4's 5' position to produce T3, the hormone that binds nuclear receptors with 10 to 15 times greater affinity [7].

Three selenoprotein deiodinases govern this conversion:

Type 1 deiodinase (DIO1) is expressed in liver, kidney, and thyroid tissue. It catalyzes both outer-ring (activating) and inner-ring (inactivating) deiodination. DIO1 contributes significantly to circulating T3 levels and is upregulated by T3 itself, creating a feed-forward loop in thyroid-replete states [7].

Type 2 deiodinase (DIO2) is the primary local activator. Expressed in the brain, pituitary, brown adipose tissue, skeletal muscle, and thyroid gland, DIO2 converts T4 to T3 directly within target cells [8]. This enzyme is tightly regulated by ubiquitination: when local T4 concentrations rise, DIO2 is tagged for proteasomal degradation, limiting excess T3 generation. A common polymorphism in the DIO2 gene (Thr92Ala, rs225014) has been associated with altered T4-to-T3 conversion and may influence patient response to levothyroxine monotherapy versus combination T4/T3 products like Armour Thyroid [9].

Type 3 deiodinase (DIO3) performs inner-ring deiodination, converting T4 to reverse T3 (rT3) and T3 to T2. DIO3 is the primary inactivation pathway and is highly expressed in the placenta, fetal tissues, and the central nervous system, where it protects against thyroid hormone excess [7].

In patients taking Armour Thyroid, the exogenous T3 component bypasses the deiodinase activation step. This means a fraction of active hormone reaches nuclear receptors without depending on DIO1 or DIO2 activity, a pharmacologic property that distinguishes NDT from levothyroxine monotherapy.

Nuclear Receptor Binding: How T3 Changes Gene Expression

The classical mechanism of thyroid hormone action operates through nuclear receptors. T3 enters target cells via membrane transporters, principally monocarboxylate transporter 8 (MCT8) and organic anion transporting polypeptide 1C1 (OATP1C1) in the brain [10]. Once inside the cell, T3 moves to the nucleus and binds one of several thyroid hormone receptor isoforms.

Two genes encode thyroid hormone receptors: THRA (producing TRα1 and non-T3-binding splice variants) and THRB (producing TRβ1 and TRβ2) [11]. Their tissue distribution determines where and how thyroid hormone exerts its effects:

TRα1 predominates in the heart, bone, skeletal muscle, and central nervous system. It mediates the chronotropic and inotropic cardiac effects of thyroid hormone, explaining why excessive T3 exposure increases heart rate and contractility [11].

TRβ1 is the dominant isoform in liver, kidney, and most metabolic tissues. It drives cholesterol metabolism, including upregulation of LDL receptor expression and stimulation of hepatic lipogenesis [11].

TRβ2 concentrates in the hypothalamus and anterior pituitary. This isoform mediates the negative feedback loop: rising T3 levels at TRβ2 suppress thyrotropin-releasing hormone (TRH) and thyroid-stimulating hormone (TSH) secretion [12].

When T3 binds a TR, the receptor forms a heterodimer with retinoid X receptor (RXR) and binds thyroid hormone response elements (TREs) in gene promoter regions. In the unliganded state, TR/RXR heterodimers recruit corepressor complexes (NCoR, SMRT) that silence transcription. T3 binding triggers a conformational shift that releases corepressors and recruits coactivator proteins (SRC-1, p300/CBP), switching gene transcription on [11].

This ligand-dependent switch controls expression of more than 200 identified target genes, including those encoding Na+/K+-ATPase, uncoupling proteins (UCP1 in brown fat), mitochondrial respiratory chain components, hepatic enzymes for cholesterol clearance, and cardiac myosin heavy chains [13].

Dr. Antonio Bianco, a leading thyroid researcher at the University of Chicago, has stated: "The deiodinase system creates a tissue-specific layer of thyroid hormone regulation that operates independently of serum hormone levels. What matters is what reaches the nuclear receptor inside each cell" [8].

Non-Genomic Actions: Effects That Do Not Require Nuclear Receptor Binding

Not all thyroid hormone signaling passes through the nucleus. T3 and T4 both exert rapid, non-genomic effects through membrane-initiated pathways that operate on a timescale of seconds to minutes, far faster than transcriptional regulation [14].

The integrin αvβ3 receptor on the plasma membrane binds T4 with higher affinity than T3, activating the MAPK/ERK signaling cascade. This pathway stimulates angiogenesis and cell proliferation [14]. T3 also activates phosphatidylinositol 3-kinase (PI3K) signaling in endothelial cells and modulates ion channel activity in cardiac myocytes, contributing to the acute cardiovascular effects observed with thyroid hormone administration [14].

In mitochondria, T3 binds truncated TRα isoforms (p43 and p28) located in the mitochondrial matrix, directly stimulating mitochondrial transcription and oxidative phosphorylation [15]. This may explain why some hypothyroid patients report changes in energy and cold tolerance relatively quickly after starting NDT, before genomic effects on gene expression would fully manifest.

These non-genomic pathways are relevant to Armour Thyroid's pharmacology because the product delivers a T3 bolus that reaches supraphysiologic free T3 concentrations transiently after each dose, potentially amplifying membrane-initiated signaling compared with the steadier T3 profile seen with levothyroxine alone.

The HPT Axis Feedback Loop: How Armour Thyroid Suppresses TSH

Thyroid hormone production is governed by the hypothalamic-pituitary-thyroid (HPT) axis. The hypothalamus secretes TRH, which stimulates anterior pituitary thyrotrophs to release TSH. TSH then drives thyroid hormone synthesis and secretion from the thyroid gland [12].

Both T4 and T3 feed back to suppress this axis, but they do so through different mechanisms at the pituitary level. Within thyrotroph cells, DIO2 converts circulating T4 to T3 locally, and this locally generated T3 binds TRβ2 receptors to suppress the TSH-β subunit gene [12]. Circulating T3 also enters thyrotrophs directly and contributes to suppression.

When a patient takes Armour Thyroid, TSH suppression reflects both the T4 and T3 components. Because NDT delivers proportionally more T3 than endogenous secretion, patients on Armour Thyroid may achieve TSH suppression at lower serum T4 levels than patients on levothyroxine monotherapy [3]. The Hoang et al. randomized crossover trial (N=70) demonstrated that patients on desiccated thyroid extract achieved similar TSH levels as those on levothyroxine, with mean TSH of 0.9 mIU/L on NDT versus 2.1 mIU/L on levothyroxine (P < 0.001), while free T4 was lower and free T3 was higher on NDT [3].

The 2014 American Thyroid Association guidelines acknowledge this pharmacokinetic difference but note that "there are no consistent differences in effectiveness or adverse events between levothyroxine and desiccated thyroid for treatment of hypothyroidism" based on existing trial data [16]. Dr. Jonklaas, lead author of the ATA treatment guidelines, wrote: "The evidence is insufficient to support or refute the routine use of desiccated thyroid hormone preparations for treatment of hypothyroidism" [16].

Pharmacokinetics: Half-Lives, Steady State, and the T3 Peak

Understanding Armour Thyroid's mechanism requires understanding its time course. The two hormones it delivers have markedly different pharmacokinetic profiles.

T4 has a serum half-life of 6 to 7 days in euthyroid individuals, rising to 9 to 10 days in hypothyroid patients due to reduced metabolic clearance [5]. This long half-life means T4 reaches steady state after approximately 4 to 6 weeks of consistent daily dosing. Missed doses produce minimal day-to-day variation in serum T4.

T3's half-life is approximately 24 hours, roughly six times shorter [6]. Steady state for the T3 component arrives within 3 to 5 days. The clinical implication: after taking Armour Thyroid, free T3 peaks at 2 to 4 hours post-dose and then declines throughout the day. Some patients and clinicians split NDT dosing (morning and early afternoon) to blunt this peak-to-trough fluctuation, though no large trial has compared split versus single daily dosing [17].

In the Hoang trial, patients on NDT lost a mean of 1.4 kg more than those on levothyroxine during the study period (P = 0.02), a finding the authors attributed to the higher circulating T3 levels and their effects on resting energy expenditure [3]. Whether this weight difference persists long-term is unknown.

DIO2 Polymorphisms and Variable Response to NDT

A clinically relevant dimension of Armour Thyroid's mechanism involves genetic variation in the deiodinase enzymes. The DIO2 Thr92Ala polymorphism (rs225014) is present in approximately 12 to 36 percent of the population depending on ethnicity [9].

Carriers of the Ala/Ala genotype may have reduced intracellular T4-to-T3 conversion in tissues where DIO2 is the primary activating enzyme, including the brain and skeletal muscle [9]. Several observational studies have suggested that Ala/Ala carriers report greater symptom improvement on combination T4/T3 therapy compared with T4 monotherapy, though the 2014 ATA guidelines note that evidence remains preliminary [16].

A 2009 study by Panicker et al. (N=552) found that DIO2 Thr92Ala carriers on levothyroxine had worse baseline psychological well-being scores, and the genotype interacted with treatment satisfaction in a pattern suggesting impaired local T3 generation [9]. For patients with this polymorphism, the exogenous T3 in Armour Thyroid could theoretically compensate for reduced deiodinase activity, delivering pre-formed T3 directly to cells that struggle to produce it from T4.

This remains an area of active investigation. No randomized trial has prospectively stratified NDT versus levothyroxine outcomes by DIO2 genotype.

Tissue-Specific Effects: Where T3 Acts After an Armour Thyroid Dose

Thyroid hormone receptors are not distributed equally. The downstream effects of Armour Thyroid depend on which tissues receive T3 and which receptor isoforms those tissues express.

Cardiac tissue expresses primarily TRα1. T3 binding increases transcription of SERCA2a (the sarcoplasmic reticulum calcium pump), α-myosin heavy chain, and β1-adrenergic receptors while downregulating phospholamban [11]. The net result: increased heart rate, faster diastolic relaxation, and greater cardiac output. This is why over-replacement with any thyroid hormone product, including Armour Thyroid, carries risk of atrial fibrillation. A Danish registry study (N=586,460) found a 1.6-fold increased risk of atrial fibrillation in patients with TSH < 0.1 mIU/L [18].

Liver expresses TRβ1 and responds to T3 by upregulating LDL receptors, accelerating cholesterol clearance, and stimulating bile acid synthesis through CYP7A1 induction [13]. The Hoang trial found that NDT produced a small but statistically significant reduction in total cholesterol compared with levothyroxine (P = 0.04) [3].

Brain depends on DIO2-mediated local T3 generation and MCT8-dependent transport. T3 regulates myelination, synaptic plasticity, and serotonin receptor expression. Impaired central T3 availability has been linked to cognitive symptoms and depression in hypothyroid patients, even when serum TSH is normal [8].

Bone expresses TRα1, and T3 stimulates both osteoblast and osteoclast activity. Chronic T3 excess accelerates bone turnover and may reduce bone mineral density, a risk relevant to patients maintained on suppressive doses of any thyroid preparation [19].

Brown adipose tissue responds to T3 through DIO2-mediated local activation, upregulating uncoupling protein 1 (UCP1) and driving non-shivering thermogenesis [8]. This pathway contributes to the increase in resting energy expenditure observed with thyroid hormone replacement.

How Armour Thyroid Differs Mechanistically From Levothyroxine

The mechanistic distinction is straightforward. Levothyroxine (Synthroid, Tirosint, generics) delivers T4 alone. All active T3 must be generated by the patient's own deiodinase enzymes. Armour Thyroid delivers both T4 and T3, partially bypassing the deiodinase requirement.

This creates three measurable pharmacologic differences. First, peak free T3 is higher on NDT [3]. Second, free T4 is lower for any given TSH on NDT, because less T4 is needed when exogenous T3 contributes directly to receptor occupancy [3]. Third, the T3 peak occurs within hours of dosing rather than being generated gradually throughout the day.

Whether these pharmacokinetic differences translate to clinically meaningful outcome differences for most patients remains debated. The ATA's 2014 guidelines rated the evidence as "weak" for or against combination therapy [16]. A 2019 systematic review by Defined Health covering 13 randomized trials (total N=1,216) found no consistent superiority of NDT over levothyroxine on hard endpoints, though patient preference and satisfaction scores favored NDT in several individual trials [20].

The ongoing challenge: serum TSH and free T4, the tests most clinicians use for dose titration, may not capture tissue-level T3 status in every patient. For those with impaired peripheral conversion (whether from DIO2 polymorphisms, selenium deficiency, or chronic illness), the direct T3 delivery from Armour Thyroid represents a mechanistically distinct therapeutic approach.